To the Editors: We read with great interest the article by Hellstrom et al. (1) about characterization of soluble mesothelin proteins (SMP) in cancer patients. The authors found that the SMP in ascites from a patient with ovarian carcinoma contained the sequence of extracellular domain of a membrane-bound mesothelin (2, 3) rather than a soluble form speculated previously by Scholler et al. (4). Their results indicate that membrane-bound mesothelin could be shed from the tumor cells to generate SMP detected in patient sera by ELISA. We agree with their conclusion that membrane-bound mesothelin is the predominant protein present in the serum and here provides direct evidence showing that such shedding does in fact take place.
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Mesothelin Is Shed from Tumor Cells
To the Editors: We read with great interest the article by Hellstrom et al. (1) about characterization of soluble mesothelin proteins (SMP) in cancer patients. The authors found that the SMP in ascites from a patient with ovarian carcinoma contained the sequence of extracellular domain of a membrane-bound mesothelin (2, 3) rather than a soluble form speculated previously by Scholler et al. (4) . Their results indicate that membrane-bound mesothelin could be shed from the tumor cells to generate SMP detected in patient sera by ELISA. We agree with their conclusion that membrane-bound mesothelin is the predominant protein present in the serum and here provides direct evidence showing that such shedding does in fact take place.
Our experiments are summarized in Fig. 1 . Using an SS1P affinity column, we purified SMP from culture supernatants of a well-documented A431/K5 cell line (3) expressing only membrane-bound mesothelin. SS1P is an immunotoxin with an Fv specific for mesothelin. About 100 ng/mL SMP was found in the culture supernatant. The molecular weight of purified SMP was f40 kDa (Fig. 1A) , consistent with the SMP described in Hellstrom et al. (1) . The full-length mesothelin precursor proteins were not detected in culture supernatant. After deglycosylation with PNGase, the molecular weight of SMP was f34 kDa. The SMP bands were cut out from a Coomassie-stained gel, protein in the gel was digested with trypsin, and the tryptic peptides were analyzed using liquid chromatography ion trap mass spectrometry (Fig. 1B) . The sequence of NH 2 terminal (EVEK) was determined by automated Edman degradation, and peptides corresponding to multiple internal regions of mesothelin were determined using the mass spectrometry/mass spectrometry mode on the ion trap mass spectrometer. Our results confirmed that the SMP was the extracellular domain of membrane-bound mesothelin shed from cells.
Mesothelin is a glycosyl-phosphatidylinositol-anchored protein. Release of such proteins from the cell surface into the serum and other body fluids can be mediated by phospholipase or proteases (5) . To determine whether the shedding of mesothelin is dependent on phosphatidylinositol-specific phospholipase C, we did anti-cross-reacting determinant assay (Prozyme, San Leandro, CA) by Western blot. The SMP was not recognized by anti-cross-reacting determinant (Anti-CRD) antibodies (Fig. 1C) .
In conclusion, our data show that the extracellular domain of membrane-bound mesothelin can be shed from tumor cells. The shedding may not require phosphatidylinositol-specific phospholipase C phospholipolysis. The precise mechanisms need further investigation. Figure 1 . A. SMPs in culture supernatant of A431/K5 cells were purified and analyzed with or without PNGase F digestion by SDS-PAGE. Recombinant bacterial mesothelin proteins (rMSLN) were used as a control. Deglyco, N-linked deglycosylation. B. SMPs were analyzed by mass spectrometry. Underline, the identified peptide sequences were aligned with membrane-bound mesothelin (MSLN). Box, NH 2 -terminal sequence. *, predicted glycosyl-phosphatidylinositol cleavage site. C. The SMP was recognized by an anti-MSLN antibody but not by an anti-cross-reacting determinant (Anti-CRD) antibody by Western blot. sVSG, soluble form of variant surface glycoprotein; mf-VSG, the membrane form of VSG.
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